INVENTIVA (EPA:IVA) Inventiva announces the design of LEGEND, a Phase IIa combination trial with lanifibranor and SGLT2 inhibitor empagliflozin in patients with NASH and type 2 diabetes
Directive transparence : information réglementée
Inventiva announces participation at several conferences in January and...
Half-Year Review of Inventiva’s Liquidity Contract with Kepler Cheuvreux
Inventiva announces positive results of clinical thorough QT study...
Inventiva reports 2021 Third Quarter Financial Information
Inventiva to host a webcast with Key Opinion Leaders from the AASLD The...
Inventiva announces participation at several conferences in November 2021
Inventiva announces the design of LEGEND, a Phase IIa combination trial...
The New England Journal of Medicine publishes the results of the NATIVE...
Inventiva announces the presentation of five scientific abstracts at the...
Inventiva announces participation at several investor conferences in...
Voir tous les communiqués de INVENTIVA
©Dissemination technology Webdisclosure.com - copyright 2022 SYMEX ECONOMICS all rights reserved